|
KMID : 1146920180480050585
|
|
Journal of Pharmaceutical Investigation
2018 Volume.48 No. 5 p.585 ~ p.593
|
|
|
A pharmacokinetic comparison of homodimer ARB-92 and heterodimer ARB-89: novel, potent antimalarial candidates derived from 7β-hydroxyartemisinin
|
|
Avery Bonnie A.
Pabbisetty Deepthi
Li Lie
Sharma Abhisheak
Gundluru Mahesh K.
Chittiboyina Amar G.
Williamson John S.
Avery Mitchell A.
|
|
|
Abstract
|
|
|
|
The ultimate goal of this study was to identify an orally active, affordable, potent and safe antimalarial drug based on the natural product artemisinin. During these efforts, a series of novel 7β-hydroxyartemisinin analogs were synthesized and characterized in vitro for their antimalarial activity against Plasmodium falciparum. Heterodimerization of 7β-hydroxyartemisinin provided the asymmetrical carbamate (ARB-89) while homodimerization provided the carbonate (ARB-92). These dimers were found to be highly active in vitro with an IC50?≤?0.50 nM against P. falciparum infected human red blood cells (RBC). For further development as potential antimalarial agents, a battery of in vitro and in vivo pharmacokinetic experiments was performed to distinguish the fate of the discovery compounds ARB-89 and ARB-92. Two UPLC-MS methods were developed and validated for the analysis of the compounds. Both ARB-89 and ARB-92 exhibited moderate affinity (51 and 56%, respectively) to parasitized RBC, which is a perquisite for antimalarial activity. Following a single dose oral and intravenous pharmacokinetic study in rats, ARB-89 displayed a high clearance (92.8?±?5.6 L/h kg), short elimination half-life (t1/2, 1.2?±?0.2 h) and moderate oral bioavailability (23.4%). ARB-89 was found to be excreted unchanged in feces, which may be due to its high lipophilicity, molecular weight and low oral exposure. In an attempt to identify a better lead antimalarial compound, ARB-92 was designed to be more water soluble than ARB-89 by incorporating a protonatable tertiary amine as part of the dimerizing ligand for 7β-hydroxyartemisinin. As anticipated, ARB-92 displayed a lower clearance (2.9?±?0.7 L/h kg) and subsequently a longer t1/2 (2.3?±?0.2 h) compared to ARB-89. The oral bioavailability of ARB-92 was found to be 34% in rats, a value somewhat better than the marketed artemisinin derivatives artenimol (19.3%), artemether (19.7%) or artesunate (29.5%).
|
|
|
KEYWORD
|
|
|
Malaria, Pharmacokinetics, Artemisinin dimers, DMPK, Protein binding
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|